QIAGEN N.V. — FY 2014 Form 20-F
Reporting period: Fiscal year ended December 31, 2014. This is an annual report, not a standalone fourth-quarter filing; the filing does not provide a clear standalone Q4 financial summary. Amounts are in U.S. dollars unless stated otherwise. Financial statements are prepared under U.S. GAAP and were audited with unqualified opinions.
Business context
QIAGEN supplies molecular sample and assay technologies, instruments, and bioinformatics to Molecular Diagnostics, Applied Testing, Pharma, and Academia customers. Consumables and related revenues represented 87% of 2014 sales; instruments represented 13%. Molecular Diagnostics accounted for approximately half of sales.
Key financial metrics
| Metric | FY 2014 | FY 2013 |
|---|---|---|
| Net sales | $1,344.8 million | $1,302.0 million |
| Gross profit / margin | $864.9 million / 64% | $815.5 million / 63% |
| Operating income / margin | $160.8 million / approximately 12% | $63.3 million / approximately 5% |
| Net income attributable to QIAGEN N.V. | $116.6 million | $69.1 million |
| Diluted earnings per share | $0.48 | $0.29 |
| Net cash from operating activities | $288.0 million | $259.0 million |
| Cash and cash equivalents | $392.7 million | $330.3 million |
| Working capital | $717.1 million | $583.9 million |
| Long-term debt, including current portion | $1,172.1 million | $845.5 million |
Year-end short-term investments were $184.0 million, in addition to cash. Current maturities of debt were $131.1 million. Capital expenditures were $86.6 million, and cash used in investing activities was $407.6 million, including $160.4 million for acquisitions and substantial net purchases of short-term investments. Total equity was $2,658.0 million, down from $2,723.9 million, with foreign-currency translation contributing to a $132.1 million comprehensive loss for the year.
Material changes versus prior year
- Sales rose 3%; management attributed about one percentage point to acquisitions and two points to the rest of the business, while currency movements reduced growth by about one point.
- Operating income and attributable net income increased from 2013, a year with substantial restructuring charges. General, administrative, integration, and related costs fell to $126.6 million from $199.1 million; 2013 included $78.1 million of restructuring costs in that category.
- Gross margin increased to 64% from 63%. Cost-of-sales restructuring and acquisition-related charges were $26.4 million in 2014, versus $40.6 million in 2013.
- U.S. HPV product sales declined 40% and represented approximately 6% of total sales. Growth in other diagnostic products, including QuantiFERON-TB and Personalized Healthcare, partly offset the decline.
- Research and development expense rose 12% to $163.6 million, reflecting acquisitions, regulatory work, and investment in bioinformatics and next-generation sequencing (NGS).
- Debt increased following issuance of $730 million of cash convertible notes in 2014, partly offset by repayment of the $300 million 2006 notes. Interest expense increased to $39.3 million from $30.9 million.
Outlook, commentary, risks, and unusual items
- Management targeted 1,500 cumulative QIAsymphony placements by year-end 2015 and expected to launch the GeneReader benchtop NGS sequencer in the second half of 2015. These are forward-looking expectations, not guarantees.
- Management expected Academia funding to improve in 2015 versus 2014, but remain below earlier levels. It also anticipated continued increases in sales and marketing and R&D spending, and possible integration and restructuring costs in 2015.
- Fourth-quarter 2014 restructuring charges totaled $37.1 million, including workforce reductions, fixed- and intangible-asset impairments, and contract and consulting costs. The company said it did not expect additional 2015 charges related to this program.
- The reported 2014 effective tax rate was approximately 1%, reflecting tax-exempt income and other jurisdictional factors. The 2013 rate was negative 85%, primarily because restructuring charges and impairments were concentrated in higher-tax jurisdictions.
- Cash convertible notes are settled in cash and include an embedded conversion derivative. The associated accounting produced non-cash interest expense and fair-value changes; the company reported $17.8 million of interest expense related to these notes in 2014. The related call options and warrants may not fully offset cash settlement exposure, and warrants could dilute shareholders if exercised.
- Principal disclosed risks include product-development and regulatory-approval uncertainty; reimbursement and pricing pressure; competition and customer concentration in U.S. HPV testing; acquisition integration and impairment risk; foreign-exchange exposure; reliance on selected suppliers; and substantial debt obligations. Litigation was described as not expected to have a material adverse effect, based on information then available.
- After year-end, QIAGEN reported that outstanding 2004 convertible notes were tendered and expected approximately $250 million of cash payments for the repurchase. It also disclosed the planned sale of QIAGEN Marseille’s business and assets, excluding its intellectual-property portfolio, for €1.2 million.
Important facts for investors to verify
- Confirm whether reported sales growth and underlying demand are sustainable, particularly given the 40% decline in U.S. HPV sales and the contribution from acquisitions.
- Track QIAsymphony placements, recurring consumables growth, QuantiFERON-TB performance, and the timing and commercial adoption of GeneReader.
- Review debt maturities, cash available after the 2004-note repurchase, covenant compliance, and the potential cash and dilution effects of the convertible-note call spread and warrants.
- Assess the durability of the 2014 operating-profit recovery after restructuring charges, along with ongoing R&D, integration, amortization, and impairment costs.
- Examine the assumptions behind the unusually low 2014 tax rate, unrecognized tax benefits, and utilization of tax-loss carryforwards.
- Review the full financial statements and notes for acquisition earn-outs, foreign-exchange impacts, and the sensitivity of goodwill and intangible assets to future performance.